Switch some teen kidney transplant patients to belatacept
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This Phase 3 study tests whether switching teens from one anti-rejection medicine to belatacept works as well as staying on the current regimen. It also looks at safety and whether patients can stay on their anti-rejection medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 12 to under 18 years old
- You received a kidney transplant at least 6 months ago
- For at least 30 days before joining, you’ve been on a stable anti-rejection plan with a calcineurin inhibitor plus mycophenolate (with or without daily steroids)
- Your kidney numbers have been stable recently (as judged by the study doctor using urine protein and eGFR)
- You had past exposure to Epstein-Barr virus (EBV) and your blood has no active EBV virus copy detected
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
This trial tests a medication called belatacept to see if it can prevent or treat early antibody-mediated rejection in kidney transplant recipients who have developed new donor-specific antibodies but still have stable kidney function.
Hear when a new Renal Allograft Recipients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.